Observational Data from Germany: Indications of Reduced Opioid Use
A practice-based analysis (Gastmeier et al., 2022) examined what happens when elderly pain patients are additionally treated with cannabis-based medicines. The results are encouraging: opioid use dropped by roughly 50% on average, with no significant adverse effects reported. Most patients were over 70 years old, suffered from chronic pain, and tolerated cannabis preparations well; in most cases, low THC doses were sufficient. The potential to reduce opioid use is particularly relevant for older patients, for whom sedation, fall risk, and respiratory depression are major concerns. While the study cannot replace randomized controlled trials (RCTs), it provides real-world evidence that medical cannabinoids can be used safely in elderly patients and may be associated with a significant reduction in opioid consumption.
New York: Long-Term Cannabis Use and Opioid Dose Reduction
Similar trends have been observed in the United States. A study by the New York State Department of Health (Nguyen et al., 2023) followed more than 8,000 patients with chronic pain who received medical cannabis. The longer the treatment lasted, the greater the reduction in opioid dosage – in some cases by more than 50%. The effect was particularly pronounced among patients with high baseline doses, who were able to lower their opioid levels substantially over time. These findings suggest that medical cannabis could help reduce overall opioid exposure and thereby decrease risks such as dependence and overdose. However, questions remain regarding the specific role of different cannabinoid formulations and the causal mechanisms underlying the association between cannabis use and opioid reduction.
Population-Level Data: Cannabis Legislation and Prescribing Behavior in the U.S.
On a broader scale, a U.S. nationwide analysis (Lozano-Rojas et al., 2025) explored how cannabis legislation affects opioid prescribing among cancer patients. The results were significat: in states that allowed cannabis dispensaries to open, opioid prescriptions decreased by about 25%. Medical cannabis thus emerges as a subtle public health factor – fewer opioids, fewer risks, improved quality of life. The findings indicate that cannabis could serve as a partial substitute for opioids in managing cancer-related pain. Still, the data are correlational, not causal. Further research is needed to understand individual mechanisms and long-term effects. Yet the evidence supports the notion that broader access to medical cannabis may have positive population-level impacts on medication use and public health outcomes.
Medical Cannabis Can Change – and Possibly Save – Lives
The evidence base is still young, but it points in a clear direction. While cannabis does not replace classical opioid therapy, it may become a credible adjunct or substitution therapy in certain areas. It enables a gentler, safer approach to pain management, especially where conventional medications reach their limits. In an aging society where people live longer and approach medication use more consciously, medical cannabis could become a genuine opportunity – for greater quality of life, less risk, and a form of medicine that once again places the individual at its center.
Anything else?
Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!
We wish you a good read!